CYP2D6 and serotonin syndrome: Given the protracted and progressive symptoms observed in this case report and others, clinicians should remain vigilant for pharmacokinetic complications such as pharmacobezoars or poor CYP2D6 metabolism in massive selective serotonin reuptake inhibitor overdose, leading to an early and aggressive treatment in similar cases with serotonin syndrome.